* If you want to update the article please login/register
Adipocytes and adipogenesis in these cells can distinguish into adipocytes and adipogenesis, reducing proliferation and stemness gene expression in these cells, according to OSCC CSCs. Induction of Adipogenic hormones may cause the cancer stem cells from OSCC tumors to die of their stemness potential. Cancer stem cells can differentiate into other lineage cells, similar to other stem cells. The proliferation and stemness gene expression in OSCC tumors can be stifled by inducing them to differentiate into adipocytes, which may be useful to find new clinical approaches in cancer therapy, such as OSCC.
Source link: https://europepmc.org/article/MED/34982245
Mesenchymal stem cells are multipotent cells that can be transplanted into the tumor microenvironment. MSCs are also implicated in TME, and we analyzed the role of MSCs in TME and discussed the connection between MSCs and liver cancer stem cells, the molecular signaling pathway pathways of MSCs promoting and inhibiting HCC, as well as MSCs' latest research findings in the treatment of HCC.
Source link: https://europepmc.org/article/MED/34981659
Primary and established hepatoma cell lines were exposed to long-term sorafenib therapy in order to demonstrate resistance generation. In three of six HCC cell lines, rapid regrowth was seen followed by rapid expansion, mimicking patient responses. Induction of sphere formation in vitro and tumor-initiating capacity in vivo, as well as an increasing number of side population and epithelial cell adhesion molecule-positive cells were shown by resistance molecule-positive cells. On the other hand, porvidible cell lines showed steady decline of TIC properties. Combined therapy of sorafenib and a specific YAP inhibitor has consistently demonstrated synergistic antioncogenic activity in resistant cell lines. YAP's comment: Transient growth of TICs and the emergence of compensatory pro-oncogenic signaling pathways may be driving antiangiogenic therapy resistance to antiangiogenic therapy. A specialized TIC therapy may be a more cost-effective therapeutic strategy to tackle HCC resistance.
Source link: https://europepmc.org/article/MED/34817932
Mesenchymal stromal cells have demonstrated promise in liver cancer therapy. Aims - To determine the effect of Hepatocellular carcinoma microenvironment on human adipose MSCs and estimate hA-MSCs intracellular miRNAs role, adds Aims. As a result of increased regulation of CAF, cancer markers, and downregulation of differentiation indicators, co-cultured hA-MSCs may have a cancer-associated phenotype, as shown by increased regulation of CAF, cancer genes, and downregulation of differentiation indicators. Increased proliferation was seen by downregulation in cell number in G0/G1, G2/M, and upregulation in cell cycle S phases. Significance This research shows an association between tumor cells and some stromal components that may lead to the formation of a cancer-associated phenotype of some CAF-like characteristics that promote cancer progression. HA-MSC signal modulation may be partially achieved by dysregulation of intracellular miR17-5P and 615-5p expression, indicating an important role in HCC pathogenesis and as a potential therapeutic agent.
Source link: https://europepmc.org/article/MED/34826437
Background/Objectives Circulating tumor cells with cancer stemness have been shown to be a direct cause of tumor formation, but no studies have reported the role of CTCs in liver transplantation for hepatocellular carcinoma. EpCAM protein was detected in HCC tissue by immunohistochemical staining. HCC was the result of LDLT recurred in four out of 25 patients, according to HCC's HCC. CTC detection by EpCAM+ or CD90+ CTCs was found to correlate well with their messenger RNA levels, according to their messenger RNA levels. In HCC tissue expressing EpCAM+ CTCs, EpCAM+ CTCs were rapidly detected in EpCAM+ CTCs. EpCAM+ CTCs were also found in HCC tissue expressing EpCAM protein. After LT, the detection of EpCAM+ CTCs or EpCAM+/CD90+ CTCs prior to surgery and/on postoperative day 1 was highly associated with HCC recurrence after LT. Independent risk factors for HCC recurrence, including Pretransplant serum PIVKA-III > 100 mAU/mL and postoperative day 1 EpCAM+/CD90+ CTCs were independent risk factors for HCC recurrence. Conclusions EpCAM+/CD90+ CTCs can be used preoperatively and 1 day after LDLT as key biological indicators in LT candidate selection and post-LDLT management.
Source link: https://europepmc.org/article/MED/34737243
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions